Lactococcus lactis strain plasma intake suppresses the incidence of dengue fever-like symptoms in healthy Malaysians: A randomized, double-blind, placebo-controlled trial

Khor, Chee-Sieng and Tsuji, Ryohei and Lee, Hai-Yen and Nor'e, Siti-Sarah and Sahimin, Norhidayu and Azman, Adzzie-Shazleen and Tiong, Vunjia and Hasandarvish, Pouya and Teoh, Boon-Teong and Soh, Yih-Harng and Chai, Jian-Hai and Kokubo, Takeshi and Kanauchi, Osamu and Yamamoto, Naoki and AbuBakar, Sazaly (2021) Lactococcus lactis strain plasma intake suppresses the incidence of dengue fever-like symptoms in healthy Malaysians: A randomized, double-blind, placebo-controlled trial. Nutrients, 13 (12). ISSN 2072-6643, DOI https://doi.org/10.3390/nu13124507.

Full text not available from this repository.

Abstract

Dengue fever (DF) is a mosquito-borne disease still with no effective treatment or vaccine available. A randomized, placebo-controlled, double-blinded, parallel-group trial was undertaken to evaluate the efficacy of oral intake of Lactococcus lactis strain plasma (LC-Plasma) on the presentation and severity of DF-like symptoms among healthy volunteers. Study participants (320) were assigned into two groups, and consumed either placebo or LC-Plasma tablets (approximately 100 billion cells/day) for 8 weeks. The clinical symptoms of DF were self-recorded through questionnaires, and exposure to DENV was determined by serum antibody and/or DENV antigen tests. No significant differences between groups were observed for exposure to DENV, or the symptomatic ratio. Results obtained showed that participants from the LC-Plasma group reported a significant reduction in the cumulative incidence days of DF-like symptoms, which include fever (p < 0.001), muscle pain (p < 0.005), joint pain (p < 0.001), and pain behind the eyes (p < 0.001), compared to that of the placebo group. Subgroup analysis revealed a significantly (p < 0.05) reduced severity score in the LC-Plasma group when study sites were separately analyzed. Overall, our findings suggest that LC-Plasma supplementation reduces the cumulative days with DF-like symptoms, and the severity of the symptoms. Daily oral intake of LC-Plasma, hence, is shown to mitigate the DF-like symptoms.

Item Type: Article
Funders: Kirin Holdings Co., Ltd., [MO002-2019]
Uncontrolled Keywords: Dengue virus;Dengue fever;LC-Plasma;Lactococcus lactis;Lactic acid bacteria
Subjects: R Medicine
R Medicine > RC Internal medicine
Divisions: Deputy Vice Chancellor (Research & Innovation) Office > Tropical Infectious Diseases Research and Education Centre
Depositing User: Ms Zaharah Ramly
Date Deposited: 17 Oct 2022 04:41
Last Modified: 17 Oct 2022 04:41
URI: http://eprints.um.edu.my/id/eprint/35289

Actions (login required)

View Item View Item